NEW YORK ( TheStreet) -- Pfizer (NYSE: PFE) hit a new 52-week high Tuesday as it traded at $19.44 compared with its previous 52-Week high of $19.39. Pfizer is changing hands at $19.41 with 1.8 million shares traded as of 9:32 a.m. ET. Average volume has been 47.1 million shares over the past 30 days.

Pfizer has a market cap of $151.1 billion and is part of the health care sector and drugs industry. Shares are up 9.9% year to date as of the close of trading on Monday.

Pfizer Inc., a biopharmaceutical company, engages in the discovery, development, manufacture, and marketing of prescription medicines for humans and animals worldwide. The company has a P/E ratio of 8.5, below the average drugs industry P/E ratio of 18.5 and below the S&P 500 P/E ratio of 21.8.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, increase in stock price during the past year, growth in earnings per share and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. You can view the full Pfizer Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.